AU2002222003A1 - Benzimidazole derivatives, preparation and therapeutic use thereof - Google Patents

Benzimidazole derivatives, preparation and therapeutic use thereof

Info

Publication number
AU2002222003A1
AU2002222003A1 AU2002222003A AU2200302A AU2002222003A1 AU 2002222003 A1 AU2002222003 A1 AU 2002222003A1 AU 2002222003 A AU2002222003 A AU 2002222003A AU 2200302 A AU2200302 A AU 2200302A AU 2002222003 A1 AU2002222003 A1 AU 2002222003A1
Authority
AU
Australia
Prior art keywords
sub
group
hydrogen atom
nr5r6
benzimidazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002222003A
Inventor
Francis Barth
Daniel Bichon
Frank Bolkenius
Viviane Van Dorsselaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0015141A external-priority patent/FR2816941B1/en
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU2002222003A1 publication Critical patent/AU2002222003A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to benzimidazole derivatives of general formula (I) in which X represents a nitrogen atom or a carbon atom; and when X represents a nitrogen atom R3 represents in particular a hydrogen atom or a (C1-C4)alkyl group, R4 represents in particular a hydrogen atom; a (C1-C6)alkyl; (C3-C7)cycloalkyl; 4-piperidyl; -(CH<SUB>2</SUB>)<SUB>p</SUB>-NR5R6; -(CH<SUB>2</SUB>)<SUB>p</SUB>-CONR5R6; -CO-(CH<SUB>2</SUB>)<SUB>p</SUB>-NR5R6; -(CH<SUB>2</SUB>)<SUB>p</SUB>-phenyl; -(CH<SUB>2</SUB>)<SUB>p</SUB>-morpholinyl; -(CH<SUB>2</SUB>)<SUB>p</SUB>-pyrrolidinyl; -(CH<SUB>2</SUB>)<SUB>p</SUB>-tetrahydroisoquinoline; -(CH<SUB>2</SUB>)<SUB>p</SUB>-heteroaryl; heteroarylcarbonyl; phenylcarbonyl; (C1-C6)alkylcarbonyl; -(CH<SUB>2</SUB>)<SUB>p</SUB>-COOR'; or phenylsulphonyl group; and when X represents a carbon atom R3 represents a hydrogen atom; a group -NR5R6; -NHCOR7; -CONHR5; -COR7; -NHCONH<SUB>2</SUB>; -OH or -CH<SUB>2</SUB>OH, R4 represents in particular a hydrogen atom; an optionally substituted group -(CH<SUB>2</SUB>)<SUB>p</SUB>-phenyl; a group -(CH<SUB>2</SUB>)<SUB>p</SUB>-heteroaryl; or a group -(CH<SUB>2</SUB>)<SUB>t</SUB>NR7R8. Preparation process and therapeutic application.
AU2002222003A 2000-11-23 2001-11-21 Benzimidazole derivatives, preparation and therapeutic use thereof Abandoned AU2002222003A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0015141 2000-11-23
FR0015141A FR2816941B1 (en) 2000-11-23 2000-11-23 BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR0106157 2001-05-10
FR0106157A FR2816942B1 (en) 2000-11-23 2001-05-10 BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
PCT/FR2001/003667 WO2002042306A1 (en) 2000-11-23 2001-11-21 Benzimidazole derivatives, preparation and therapeutic use thereof

Publications (1)

Publication Number Publication Date
AU2002222003A1 true AU2002222003A1 (en) 2002-06-03

Family

ID=26212744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002222003A Abandoned AU2002222003A1 (en) 2000-11-23 2001-11-21 Benzimidazole derivatives, preparation and therapeutic use thereof

Country Status (8)

Country Link
US (1) US6979683B2 (en)
EP (1) EP1339719B1 (en)
JP (1) JP2004514678A (en)
AT (1) ATE269335T1 (en)
AU (1) AU2002222003A1 (en)
DE (1) DE60103928T2 (en)
FR (1) FR2816942B1 (en)
WO (1) WO2002042306A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339402B1 (en) * 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
RU2476224C2 (en) * 2010-11-12 2013-02-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Российской академии медицинских наук (ФГБУ "НИИ фармакологии имени В.В. Закусова" РАМН) Drug preparation with cardioprotective activity
ES2910071T3 (en) 2018-03-08 2022-05-11 Incyte Corp Aminopyrazine diol compounds as PI3K-Y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710915B1 (en) * 1993-10-04 1995-11-24 Synthelabo Piperidine derivatives, their preparation and their therapeutic use.
FR2731708B1 (en) * 1995-03-13 1997-04-30 Synthelabo PIPERIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
USRE39608E1 (en) * 1998-11-27 2007-05-01 Abbott Gmbh & Co. Kg Substituted benzimidazoles and their use as PARP inhibitors
ECSP003637A (en) * 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES

Also Published As

Publication number Publication date
DE60103928D1 (en) 2004-07-22
FR2816942A1 (en) 2002-05-24
EP1339719A1 (en) 2003-09-03
US20040029866A1 (en) 2004-02-12
FR2816942B1 (en) 2003-05-09
DE60103928T2 (en) 2005-07-14
ATE269335T1 (en) 2004-07-15
WO2002042306A1 (en) 2002-05-30
JP2004514678A (en) 2004-05-20
US6979683B2 (en) 2005-12-27
EP1339719B1 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
NL350075I2 (en)
MXPA02012033A (en) 2-aminocarbonyl-9h-purine derivatives.
GB9917408D0 (en) Compounds
EP1400529A4 (en) Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
NO2011022I2 (en) Pradofloxacin, its pharmaceutically acceptable hydrates and acid addition salts as well as alkaline, alkaline earth, silver and guanidinium salts
AU1816901A (en) Benzimidazole compounds having nociceptin receptor affinity
MY132106A (en) New pyridazin-3(2h)-one derivatives
YU7203A (en) Benzimidazole derivatives, preparation and therapeutic use thereof
MXPA04002035A (en) 1, 8-naphthyridine derivatives as antidiabetics.
GB0007405D0 (en) Compounds
WO2007099162A3 (en) Hydroxylated long-chain resveratrol derivatives useful as neurotrophic agents
AP2001002302A0 (en) 13-Methyl erythromycin derivatives.
AU2001286768A1 (en) Novel macrocycles and uses thereof
GB9300194D0 (en) Piperazine derivatives
WO2001000554A3 (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
PL341514A1 (en) Substituted compounds of 2-benzylamino-2-phenyl acetamide
IL150061A0 (en) Purine derivatives
AU2002222003A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AP9801377A0 (en) Tricyclic erythromycin derivatives.
AU2003294092A1 (en) Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics
MXPA03001356A (en) Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments.
BG104034A (en) Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect
NO20022123L (en) Oxoxazole derivatives for use as inhibitors of phosphodiesterase VII